| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Ikena Oncology Inc (NASDAQ: IKNA)
IKNA Technical Analysis
2
| As on 9th Jun 2023 IKNA STOCK Price closed @ 6.51 and we RECOMMEND Buy for LONG-TERM with Stoploss of 5.95 & Strong Sell for SHORT-TERM with Stoploss of 10.60 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IKNASTOCK Price
| Open | 6.79 | Change | Price | % |
| High | 6.94 | 1 Day | -0.28 | -4.12 |
| Low | 6.51 | 1 Week | 0.54 | 9.05 |
| Close | 6.51 | 1 Month | 1.61 | 32.86 |
| Volume | 41048 | 1 Year | -6.79 | -51.05 |
| 52 Week High 15.04 | 52 Week Low 2.00 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| IKNA Daily Charts |
IKNA Intraday Charts |
Whats New @ Bazaartrend |
IKNA Free Analysis |
|
|
IKNA Important Levels Intraday
| RESISTANCE | 7.34 |
| RESISTANCE | 7.07 |
| RESISTANCE | 6.91 |
| RESISTANCE | 6.74 |
| SUPPORT | 6.28 |
| SUPPORT | 6.11 |
| SUPPORT | 5.95 |
| SUPPORT | 5.68 |
IKNA Forecast April 2024
| 4th UP Forecast | 16.88 |
| 3rd UP Forecast | 13.55 |
| 2nd UP Forecast | 11.5 |
| 1st UP Forecast | 9.44 |
| 1st DOWN Forecast | 3.58 |
| 2nd DOWN Forecast | 1.52 |
| 3rd DOWN Forecast | -0.53 |
| 4th DOWN Forecast | -3.86 |
IKNA Weekly Forecast
| 4th UP Forecast | 12.81 |
| 3rd UP Forecast | 10.79 |
| 2nd UP Forecast | 9.54 |
| 1st UP Forecast | 8.29 |
| 1st DOWN Forecast | 4.73 |
| 2nd DOWN Forecast | 3.48 |
| 3rd DOWN Forecast | 2.23 |
| 4th DOWN Forecast | 0.21 |
IKNA Forecast2024
| 4th UP Forecast | 33.14 |
| 3rd UP Forecast | 24.6 |
| 2nd UP Forecast | 19.32 |
| 1st UP Forecast | 14.04 |
| 1st DOWN Forecast | -1.02 |
| 2nd DOWN Forecast | -6.3 |
| 3rd DOWN Forecast | -11.58 |
| 4th DOWN Forecast | -20.12 |
Ikena Oncology Inc ( NASDAQ USA Symbol : IKNA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IKNA Business Profile
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Address: 645 Summer Street, Boston, MA, United States, 02210
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service